文献速递泌尿男性生殖肿瘤头颈与中枢神经肿瘤

卡博替尼治疗肾细胞癌脑转移的临床活性与安全性

Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma.
PubMed 文献 · JAMA Oncol · 2021-01-01

队列A(33例,38%)为脑转移进展且未同期接受脑部局部治疗者,队列B(55例,62%)为稳定或进展的脑转移并同期接受脑部局部治疗者。两队列颅内缓解率分别为55%(95%CI 36%-73%)和47%(95%CI 33%-61%),卡博替尼耐受性良好,未见非预期毒性或神经不良事件,无治疗相关死亡。

要点

  • 卡博替尼在肾细胞癌脑转移中显示可观颅内活性,队列A颅内缓解率55%。
  • 队列B颅内缓解率47%,两队列均观察到颅内获益。
  • 卡博替尼耐受性良好,未见非预期毒性或神经不良事件。

核心结论

  • 卡博替尼在肾细胞癌脑转移患者中显示出可观的颅内活性和可接受的安全性。
  • 支持开展前瞻性研究评估卡博替尼对肾细胞癌脑转移的疗效。

研究设计与样本

  • 队列A为脑转移进展且未同期接受脑部局部治疗者(33例,38%),队列B为稳定或进展的脑转移并同期接受脑部局部治疗者(55例,62%)。
  • 暴露为任何治疗线数的卡博替尼单药治疗,中位随访17个月(范围2-74个月)。

主要发现

  • 队列A颅内缓解率为55%(95%CI 36%-73%),队列B为47%(95%CI 33%-61%)。
  • 队列A颅外缓解率48%(95%CI 31%-66%),中位至治疗失败时间8.9个月(95%CI 5.9-12.3个月),中位总生存15个月(95%CI 9.0-30.0个月)。
  • 队列B颅外缓解率38%(95%CI 25%-52%),中位至治疗失败时间9.7个月(95%CI 6.0-13.2个月),中位总生存16个月(95%CI 12.0-21.9个月)。
  • 卡博替尼耐受性良好,未见非预期毒性或神经不良事件,无治疗相关死亡。

关键数值与推荐

  • 颅内缓解率按修改版实体瘤疗效评价标准1.1版评估。
  • 队列A颅内缓解率55%(95%CI 36%-73%),队列B为47%(95%CI 33%-61%)。

临床怎么用

  • 对于肾细胞癌脑转移患者,卡博替尼可作为具有颅内活性的全身治疗选择。
  • 卡博替尼的安全性支持其在脑转移患者中的应用,但需前瞻性研究进一步验证。

局限性

  • 本研究为回顾性队列研究,样本量有限(88例)。
  • 队列A与队列B在脑部局部治疗上存在差异,可能影响结果解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with brain metastases from renal cell carcinoma (RCC) have been underrepresented in clinical trials, and effective systemic therapy is lacking. Cabozantinib shows robust clinical activity in metastatic RCC, but its effect on brain metastases remains unclear. OBJECTIVE: To assess the clinical activity and toxic effects of cabozantinib to treat brain metastases in patients with metastatic RCC. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included patients with metastatic RCC and brain metastases treated in 15 international institutions (US, Belgium, France, and Spain) between January 2014 and October 2020. Cohort A comprised patients with progressing brain metastases without concomitant brain-directed local therapy, and cohort B comprised patients with stable or progressing brain metastases concomitantly treated by brain-directed local therapy. EXPOSURES: Receipt of cabozantinib monotherapy at any line of treatment. MAIN OUTCOMES AND MEASURES: Intracranial radiological response rate by modified Response Evaluation Criteria in Solid Tumors, version 1.1, and toxic effects of cabozantinib. RESULTS: Of the 88 patients with brain metastases from RCC included in the study, 33 (38%) were in cohort A and 55 (62%) were in cohort B; the majority of patients were men (n = 69; 78%), and the median age at cabozantinib initiation was 61 years (range, 34-81 years). Median follow-up was 17 months (range, 2-74 months). The intracranial response rate was 55% (95% CI, 36%-73%) and 47% (95% CI, 33%-61%) in cohorts A and B, respectively. In cohort A, the extracranial response rate was 48% (95% CI, 31%-66%), median time to treatment failure was 8.9 months (95% CI, 5.9-12.3 months), and median overall survival was 15 months (95% CI, 9.0-30.0 months). In cohort B, the extracranial response rate was 38% (95% CI, 25%-52%), time to treatment failure was 9.7 months (95% CI, 6.0-13.2 months), and median overall survival was 16 months (95% CI, 12.0-21.9 months). Cabozantinib was well tolerated, with no unexpected toxic effects or neurological adverse events reported. No treatment-related deaths were observed. CONCLUSIONS AND RELEVANCE: In this cohort study, cabozantinib showed considerable intracranial activity and an acceptable safety profile in patients with RCC and brain metastases. Support of prospective studies evaluating the efficacy of cabozantinib for brain metastases in patients with RCC is critical.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Hirsch L, Martinez Chanza N, Farah S, et al. Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. JAMA Oncol. 2021. PMID: 34673916. doi:10.1001/jamaoncol.2021.4544

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。